Tech Company Financing Transactions
QuatRx Pharmaceuticals Funding Round
On 5/22/2007, QuatRx Pharmaceuticals secured $44 million in Series E funding from Venrock, Biomedical Investments and Frazier Healthcare Partners.
Transaction Overview
Company Name
Announced On
5/22/2007
Transaction Type
Debt
Venture Equity
Venture Equity
Amount
$44,000,000
Round
Series E
Investors
Proceeds Purpose
The new round of funding will be used
primarily to complete ongoing Phase 3 and Phase 2 clinical studies of
QuatRx's two endocrine programs, Ophena(TM) and fispemifene, and Phase 1
clinical studies with its lipid-lowering compound, QRX-431.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
777 East Eisenhower Pkwy. 100
Ann Arbor, MI 48108
USA
Ann Arbor, MI 48108
USA
Phone
Website
Email Address
Overview
QuatRx Pharmaceuticals Company is a pharmaceutical company focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Zerbe
Chief Financial Officer
Gary Onn
Chief Operating Officer
Christopher Nicholas
Chief Scientific Officer
Stuart Dombey
Browse more venture capital transactions:
Prev: 5/22/2007: SnapLogic venture capital transaction
Next: 5/23/2007: Cerulean Pharma venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs